These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31094239)

  • 1. Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis.
    De Giglio L; Grimaldi AE; Fubelli F; Marinelli F; Pozzilli C
    Expert Rev Neurother; 2019 May; 19(5):417-429. PubMed ID: 31094239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in treatment of multiple sclerosis.
    Rommer PS; Dudesek A; Stüve O; Zettl UK
    Clin Exp Immunol; 2014 Mar; 175(3):373-84. PubMed ID: 24001305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A safety review of current monoclonal antibodies used to treat multiple sclerosis.
    Costa GD; Comi G
    Expert Opin Drug Saf; 2023; 22(11):1011-1024. PubMed ID: 37314699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.
    Gabelić T; Barun B; Adamec I; Krbot Skorić M; Habek M
    Hum Vaccin Immunother; 2021 Nov; 17(11):4345-4362. PubMed ID: 34668842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of monoclonal antibodies for the treatment of multiple sclerosis.
    McGinley MP; Moss BP; Cohen JA
    Expert Opin Drug Saf; 2017 Jan; 16(1):89-100. PubMed ID: 27756172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review.
    Scotto R; Reia A; Buonomo AR; Moccia M; Viceconte G; Pisano E; Zappulo E; Brescia Morra V; Gentile I
    Expert Opin Drug Saf; 2021 Aug; 20(8):925-936. PubMed ID: 33880975
    [No Abstract]   [Full Text] [Related]  

  • 7. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
    Rommer PS; Zettl UK
    Expert Opin Pharmacother; 2018 Apr; 19(5):483-498. PubMed ID: 29528247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects.
    Weber MS; Menge T; Lehmann-Horn K; Kronsbein HC; Zettl U; Sellner J; Hemmer B; Stüve O
    Curr Pharm Des; 2012; 18(2):209-19. PubMed ID: 22229582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the risk of multiple sclerosis disease-modifying therapies.
    Ayrignac X; Bilodeau PA; Prat A; Girard M; Labauge P; Le Lorier J; Larochelle C; Duquette P
    Expert Rev Neurother; 2019 Jul; 19(7):695-706. PubMed ID: 31195842
    [No Abstract]   [Full Text] [Related]  

  • 11. Monoclonal Antibodies for Multiple Sclerosis: An Update.
    Graf J; Aktas O; Rejdak K; Hartung HP
    BioDrugs; 2019 Feb; 33(1):61-78. PubMed ID: 30604390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1857-65. PubMed ID: 24993136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review.
    Ng HS; Rosenbult CL; Tremlett H
    Expert Opin Drug Saf; 2020 Sep; 19(9):1069-1094. PubMed ID: 32799563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Risks with Immune Therapies in Multiple Sclerosis.
    Förster M; Küry P; Aktas O; Warnke C; Havla J; Hohlfeld R; Mares J; Hartung HP; Kremer D
    Drug Saf; 2019 May; 42(5):633-647. PubMed ID: 30607830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S; Weinstock-Guttman B
    Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab: a country-based surveillance program.
    Mancardi GL; Amato MP; D'Alessandro R; Drago F; Milanese C; Popoli P; Provinciali L; Rossi P; Savettieri G; Tedeschi G; Tola MR; Vanacore N; Covezzoli A; De Rosa M; Piccinni C; Montanaro N; Periotto L; Addis A; Martini N
    Neurol Sci; 2008 Sep; 29 Suppl 2():S235-7. PubMed ID: 18690503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of antibody therapy in demyelinating diseases.
    Akaishi T; Nakashima I
    Int Immunol; 2017 Jul; 29(7):327-335. PubMed ID: 28910968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis.
    Moiola L; Rommer PS; Zettl UK
    Curr Opin Neurol; 2020 Jun; 33(3):286-294. PubMed ID: 32374570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.